Parnell Pharmaceuticals Holdings Ltd
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PARNF research report →
Companywww.parnell.com
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U. S.
- CEO
- Brad R. McCarthy CPA
- IPO
- 2014
- HQ
- Alexandria, NSW, AU
Price Chart
Valuation
- Market Cap
- $1.68M
- P/E
- -2.30
- P/S
- 0.07
- P/B
- -0.09
- EV/EBITDA
- 10.21
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 56.39%
- Op Margin
- 3.94%
- Net Margin
- -4.16%
- ROE
- 4.26%
- ROIC
- 4.66%
Growth & Income
- Revenue
- $34.17M · 13.88%
- Net Income
- $-1,419,593 · 90.57%
- EPS
- $-0.05 · 93.95%
- Op Income
- $1.35M
- FCF YoY
- 182.99%
Performance & Tape
- 52W High
- $0.35
- 52W Low
- $0.00
- 50D MA
- $0.08
- 200D MA
- $0.05
- Beta
- 626.88
- Avg Volume
- 1
Get TickerSpark's AI analysis on PARNF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PARNF Coverage
We haven't published any research on PARNF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PARNF Report →